⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 28, 2026British Journal of HaematologyOpen Access

Impact of CD34 ⁺ cell dose on outcomes of related allogeneic PBSCT in adult AML patients

Yusuke Toda Tomoyasu Jo Yasuyuki Arai Kaito Harada Masamitsu Yanada Takahiro Fukuda Satoshi Yoshihara Noriko Doki Naoyuki Uchida Yasuo Mori Yuta Hasegawa Yukio Kondo Toshiro Kawakita Tetsuya Eto Tetsuya Nishida Masatsugu Tanaka Makoto Onizuka Katsuhiro Shono Masayuki Hino Tatsuo Ichinohe Yoshiko Atsuta Takaaki Konuma

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research investigates how varying doses of CD34+ cells affect recovery and complications in adult patients undergoing allogeneic PBSCT for AML.
Evaluated the effect of CD34+ cell dosing on platelet engraftment and graft failure in adult AML patients.
Measured outcomes included platelet recovery times and incidence of secondary graft failures.
Higher CD34+ cell doses improved platelet engraftment rates.
There was a reduced risk of secondary graft failure without additional long-term benefits documented.

Implication

Evaluates platelet engraftment and graft failure risk in adult AML patients, suggesting optimal CD34+ cell dosing.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Toda et al. (2026) studied this question.

synapsesocial.com/papers/69f2f19c1e5f7920c63873c1 https://doi.org/10.1111/bjh.70506

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Impact of CD34+ cell dose on outcomes of haploidentical peripheral blood stem cell transplantation in acute leukemia2025 · 2 citations
2CD34 selected stem cell boost provides robust outcomes in patients with poor graft function2025
3Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival2024 · 6 citations
4CD 34 stem cell boost in patients with poor graft function after allogeneic hematopoietic stem cell transplantation: Experience from a tertiary care center2025
5High <scp>CD34</scp>‐positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft‐versus‐host disease or mortality2024 · 2 citations

CD34 <sup>+</sup> cell dose - Predictors and effect on patient outcome in hematopoietic stem cell transplant2026
CD34+ Selected Cells For The Treatment Of Poor Graft Function Following Allogeneic Stem Cell Transplantation2013
Impact of the number of cryopreserved <scp>CD34</scp><sup>+</sup> cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the <scp>GOA</scp> study2022
Ageing and female sex progressively remodel B‐ and T‐cell compartments to strain peripheral T‐cell tolerance to red blood cell autoantigensBritish Journal of Haematology · 2026
Second allogeneic haematopoietic stem cell transplantation for non‐malignant diseasesBritish Journal of Haematology · 2026

More from British Journal of Haematology

More from The University of Tokyo

More from Kyoto University

More from Hiroshima University

More from Tokyo Metropolitan University

More from Tokai University

More from Nagoya City University

More from Tokyo Medical University

More from Kyoto University Hospital

More from Toranomon Hospital

More from Aichi Medical University

More from Tokyo Metropolitan Komagome Hospital

More from Kanagawa Cancer Center

More from Kanagawa Prefectural Hospital Organization

More from Hokkaido University Hospital

More from Kyushu University Hospital

More from Kumamoto Medical Center

More from Hamanomachi Hospital

More from Toyama Prefectural Central Hospital

More from Japanese Red Cross Nagoya Daiichi Hospital

More from The Japanese Data Center for Hematopoietic Cell Transplantation

More from Chiba Aoba Municipal Hospital